• Carlos Romero Gómez, Halbert Hernández Negrín, and María Del Mar Ayala Gutiérrez.
• Internal Medicine Department, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA), Málaga, España. Electronic address: carlosrg1968@gmail.com.
• Med Clin (Barc). 2023 Apr 6; 160 (7): 310317310-317.

AbstractEosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by the presence of asthma associated with eosinophilia, eosinophilic infiltration of different organs, and vasculitis of small and medium-sized vessels. Although classified as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, it occurs in less than half of the patients. The disease is infrequent, typically appearing in patients with asthma and affecting multiple organs such as lung, skin and peripheral nervous system. Treatment has been based on the use of glucocorticoids and immunosuppressants. In recent years, progress has been made in the knowledge of the pathophysiology, in treatment with the inclusion of biologic agents, the classification criteria have been revised and new therapeutic recommendations have been published.Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

23 keywords...

hide…